bioAffinity
  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Select Page

Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer

by Maria Zannes | May 8, 2025 | Press Releases

Dr. Gordon Downie shares case-based evidence demonstrating how CyPath® Lung improves diagnostic confidence and guides care in high-risk patients  SAN ANTONIO, TX — May 8, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on...

bioAffinity Technologies Announces Closing of $3.25 Million Offering

by Maria Zannes | May 7, 2025 | Press Releases

SAN ANTONIO, Texas (May 7, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has closed its previously announced best efforts...

bioAffinity Technologies Announces Pricing of $3.25 Million Offering

by Maria Zannes | May 6, 2025 | Press Releases

SAN ANTONIO, Texas (May 6, 2025) – bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW) a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it has priced a best efforts offering of securities...

bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost

by Maria Zannes | Apr 17, 2025 | Press Releases

Process optimization enhances data acquisition and processing speed, lowers reagent costs, and maintains test performance for early lung cancer detection SAN ANTONIO, TX – (April 17, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company...

bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024

by Maria Zannes | Mar 31, 2025 | Press Releases

Increased Demand, Expanded Insurance Coverage Drive Record Growth  SAN ANTONIO, Texas (March 31, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage...
« Older Entries

Categories

  • Articles (27)
  • Events (38)
  • News (52)
  • Press Releases (119)
  • Publications (17)

Recent Posts

  • Independent White Paper Highlights Real-World Impact of bioAffinity Technologies’ CyPath® Lung in Diagnosing Early-Stage Lung Cancer May 8, 2025
  • bioAffinity Technologies Announces Closing of $3.25 Million Offering May 7, 2025
  • bioAffinity Technologies Announces Pricing of $3.25 Million Offering May 6, 2025
  • bioAffinity Technologies Increases Efficiency of CyPath® Lung Test by Boosting Data Acquisition Throughput by 50% and Reducing Unit Cost April 17, 2025
  • bioAffinity Technologies Reports Record $9.4 Million Revenue for 2024 March 31, 2025

Learn About CyPath Lung

CyPath Lung Test

Main Menu

  • Home
  • Publications
  • News
  • About Us
  • Videos
  • Contact
  • Investor Relations
  • Careers
Copyright © 2023 bioAffinity Technologies, Inc.